title: Pharmaceutical approval update.
abstract: Albiglutide (Tanzeum) for type-2 diabetes, ramucirumab (Cyramza) for advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma, and ceritinib (Zykadia) for metastatic non-small-cell lung cancer.
authors.forename: Marvin M
authors.initials: MM
authors.lastname: Goldenberg